[go: up one dir, main page]

PE20200611A1 - Formulacion del inhibidor stat3 - Google Patents

Formulacion del inhibidor stat3

Info

Publication number
PE20200611A1
PE20200611A1 PE2019001997A PE2019001997A PE20200611A1 PE 20200611 A1 PE20200611 A1 PE 20200611A1 PE 2019001997 A PE2019001997 A PE 2019001997A PE 2019001997 A PE2019001997 A PE 2019001997A PE 20200611 A1 PE20200611 A1 PE 20200611A1
Authority
PE
Peru
Prior art keywords
stat3
inhibitor
formulation
amino
salt
Prior art date
Application number
PE2019001997A
Other languages
English (en)
Inventor
Robert H Shoemaker
Jonathan M White
Shanker Gupta
Michael W Lovell
Original Assignee
The United States Of America As Represented By The Secretary Dept Of Health And Human Services
Glg Pharma Llc
Mriglobal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America As Represented By The Secretary Dept Of Health And Human Services, Glg Pharma Llc, Mriglobal filed Critical The United States Of America As Represented By The Secretary Dept Of Health And Human Services
Publication of PE20200611A1 publication Critical patent/PE20200611A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a una sal de acido benzoico 2-hidroxi-4-[[2-[[(4-metilfenil)sulfonil]oxi]acetil]amino] y 2-amino-2-(hidroximetil)-1,3-propanediol, la cual es soluble en agua y estable por periodos de tiempo prolongados. Dicha sal es un inhibidor de STAT3. Tambien se refiere a una composicion farmaceutica que la comprende siendo util en el tratamiento o prevencion del cancer de mama.
PE2019001997A 2017-04-05 2018-04-05 Formulacion del inhibidor stat3 PE20200611A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481960P 2017-04-05 2017-04-05
PCT/US2018/026228 WO2018187551A1 (en) 2017-04-05 2018-04-05 Stat3 inhibitor formulation

Publications (1)

Publication Number Publication Date
PE20200611A1 true PE20200611A1 (es) 2020-03-10

Family

ID=62067809

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001997A PE20200611A1 (es) 2017-04-05 2018-04-05 Formulacion del inhibidor stat3

Country Status (15)

Country Link
US (1) US10913709B2 (es)
EP (1) EP3606515B1 (es)
JP (1) JP2020513022A (es)
KR (1) KR20200043930A (es)
CN (1) CN110944631A (es)
AU (1) AU2018248303A1 (es)
BR (1) BR112019020985A2 (es)
CA (1) CA3058973A1 (es)
CL (1) CL2019002843A1 (es)
CO (1) CO2019012386A2 (es)
ES (1) ES2888235T3 (es)
MX (1) MX386463B (es)
PE (1) PE20200611A1 (es)
PL (1) PL3606515T3 (es)
WO (1) WO2018187551A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191285B1 (en) 1997-07-03 2001-02-20 Abbott Laboratories Process for the preparation of ketorolac tromethamine
WO2007136858A2 (en) * 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
WO2010062681A2 (en) 2008-10-30 2010-06-03 University Of South Florida Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
AU2009322625A1 (en) 2008-12-01 2011-07-21 University Of Central Florida Research Foundation, Inc. Drug composition cytotoxic for pancreatic cancer cells
US9572787B2 (en) 2011-05-19 2017-02-21 Rhode Island Hospital Inhibition of renal fibrosis
WO2016054998A1 (en) * 2014-10-08 2016-04-14 Shih-Chieh Hung Method for inhibiting survival, tumorigenesis and metastasis of cancer cells and/or cancer stem cells

Also Published As

Publication number Publication date
MX2019011913A (es) 2021-09-24
CN110944631A (zh) 2020-03-31
WO2018187551A1 (en) 2018-10-11
US10913709B2 (en) 2021-02-09
AU2018248303A1 (en) 2019-11-07
PL3606515T4 (pl) 2022-02-14
EP3606515A1 (en) 2020-02-12
CO2019012386A2 (es) 2020-01-31
CL2019002843A1 (es) 2020-06-12
KR20200043930A (ko) 2020-04-28
JP2020513022A (ja) 2020-04-30
BR112019020985A2 (pt) 2020-05-05
ES2888235T3 (es) 2022-01-03
EP3606515B1 (en) 2021-06-02
CA3058973A1 (en) 2018-10-11
MX386463B (es) 2025-03-18
PL3606515T3 (pl) 2022-02-14
US20200109109A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
PE20171238A1 (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
MX2014002252A (es) Proceso de remineralizacion de agua desalinizada y dulce dosificando una solucion de carbonato de calcio en agua blanda.
CL2013002166A1 (es) Compuesto correspondiente a la sal de magnesio del acido (s)-alfa-etoxi-4-[2-metil-5-[4-metiltiofenil-1h-pirrol-1-il]etoxi]bencenpropanoico; composicion farmaceutica que lo comprende; y uso para el tratamiento de lipodistrofia.
MX388474B (es) Composiciones que contienen tucaresol o sus análogos.
BR112017004798A2 (pt) composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal
CL2019002677A1 (es) Composición adhesiva y método de preparación de la misma.
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
MX2016010169A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
MX369642B (es) Sales de dasatinib.
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
MX2015016057A (es) Solucion estabilizada de acido hipocloroso y uso de la misma.
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
CY1124724T1 (el) Συνθεση δυο συστατικων που περιλαμβανει ακετυλοσαλικυλικο οξυ
BR112013020456A2 (pt) nova composição antifúngica
MX2014003840A (es) Metodo para reducir la transpiracion y composiciones antitranspirantes.
CL2017000230A1 (es) Composición adhesiva
BR112017011912A2 (pt) agente para o tratamento contra deformação do cabelo
ES2511940B2 (es) Sistema para la determinación simultánea de cationes y aniones en muestras acuosas mediante ICP-AES
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
PE20200611A1 (es) Formulacion del inhibidor stat3